Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL-DOSE: 150 IU vs 225 IU FSH in IVF/ICSI for Predicted Normal Responders
NCT07346235Phase 3Withdrawn
- Sponsor
- American Hospital
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of follicle-stimulating hormone in female infertility (2 arms), sponsored by American Hospital. Primary endpoint: Cumulative Live Birth Rate per Initiated Cycle at 12 months. Planned start Mar 2026; status: withdrawn.
02
Drugs
follicle-stimulating hormone
03
Conditions
female infertility
Beyond the preview
Go deeper on NCT07346235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346235.